Post-COVID Supply Chain Opportunities And Strategies For Biopharmas And CDMOs

By Derron Stark and Jay Welsh

The COVID-19 pandemic exposed the dependence on global supply chains, as well as the limited domestic manufacturing capacity in the U.S. for critical medicines and medical devices. Recurring drug and medical device shortages and quality issues related to offshoring also have encouraged U.S. commercial customers to purchase from domestic manufacturers. The government policy response has been an intense focus on building up domestic manufacturing capabilities.